NCT02490787 is a Phase 1 clinical trial of Concizumab in Congenital Bleeding Disorder, sponsored by Novo Nordisk A/S.

Who is sponsoring NCT02490787?

NCT02490787 is sponsored by Novo Nordisk A/S.

What drugs are being tested in NCT02490787?

Interventions in NCT02490787: Concizumab, placebo.

What condition does NCT02490787 study?

NCT02490787 studies Congenital Bleeding Disorder, Haemophilia A.

Is NCT02490787 still recruiting?

NCT02490787 is currently completed. Last updated 21 July 2017.

Last reviewed 2017-07-21 · How we verify

NCT02490787

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects

Completed Phase 1 Last updated 21 July 2017

What this trial tests

Phase 1 trial testing Concizumab in Congenital Bleeding Disorder in 24 participants. Completed in 14 October 2016.

Timeline

10 September 2015

Primary endpoint
14 October 2016

14 October 2016

Quick facts

Lead sponsor	Novo Nordisk A/S
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	double
Primary purpose	treatment
Enrollment	24
Start date	10 September 2015
Primary completion	14 October 2016
Estimated completion	14 October 2016
Sites	34 locations across France, Netherlands, Malaysia, Ukraine, Austria, United Kingdom, Germany, Israel

Drugs / interventions tested

Concizumab (CONCIZUMAB) — full drug profile →
placebo

Conditions studied

Congenital Bleeding Disorder — all drugs for Congenital Bleeding Disorder →
Haemophilia A — all drugs for Haemophilia A →

Sponsor

Novo Nordisk A/S — full company profile →

Who can join

Adults 18 to 64, male only, with Congenital Bleeding Disorder or Haemophilia A. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial is conducted globally. The aim of this trial is to investigate safety, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of concizumab administered subcutaneously to haemophilia A subjects.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

A Molecular Revolution in the Treatment of Hemophilia.
Butterfield JSS, Hege KM, Herzog RW, Kaczmarek R. · · 2020 · cited 76× · PMID 31843450 · DOI 10.1016/j.ymthe.2019.11.006
A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A.
Eichler H, Angchaisuksiri P, Kavakli K, Knoebl P, et al · · 2018 · cited 57× · PMID 30137664 · DOI 10.1111/jth.14272
Novel therapies and current clinical progress in hemophilia A.
Balkaransingh P, Young G. · · 2018 · cited 37× · PMID 29387330 · DOI 10.1177/2040620717746312
Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data.
Eichler H, Angchaisuksiri P, Kavakli K, Knoebl P, et al · · 2019 · cited 26× · PMID 30408848 · DOI 10.1111/hae.13627
Updates on Novel Non-Replacement Drugs for Hemophilia.
Gualtierotti R, Pasca S, Ciavarella A, Arcudi S, et al · · 2022 · cited 22× · PMID 36297295 · DOI 10.3390/ph15101183
Non-factor therapies for bleeding disorders: A primer for the general haematologist.
Swan D, Mahlangu J, Thachil J. · · 2022 · cited 18× · PMID 36051064 · DOI 10.1002/jha2.442
Progress in the Development of Anti-tissue Factor Pathway Inhibitors for Haemophilia Management.
Mahlangu JN. · · 2021 · cited 18× · PMID 34026796 · DOI 10.3389/fmed.2021.670526
Novel alternate hemostatic agents for patients with inhibitors: beyond bypass therapy.
Ragni MV. · · 2017 · cited 6× · PMID 29222310 · DOI 10.1182/asheducation-2017.1.605

Verify or expand the search:

Other trials of Concizumab

Trials testing the same drug.

NCT06831734 — Post-marketing Surveillance (Special Use-results Surveillance) on Treatment With Alhemo · enrolling by invitation
NCT06285071 — Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophi · enrolling by invitation
NCT06234813 — Targeting TFPI With Concizumab to Improve Haemostasis in Glanzmann Thrombasthenia Patients: an in Vitro Study · NA · completed
NCT05135559 — A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors · Phase 3 · active not recruiting
NCT04082429 — Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors · Phase 3 · active not recruiting

Other recruiting trials for Congenital Bleeding Disorder

Currently open trials in the same condition.

NCT06574984 — Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients · recruiting

Other Novo Nordisk A/S trials

Trials by the same sponsor.

NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02490787 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
Last refreshed: 21 July 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02490787.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing